< 0 1 0 1 O
6 1 2 1 2 B-upper_bound
months 3 9 3 9 I-upper_bound
after 10 15 10 15 O
myocardial 16 26 16 26 B-chronic_disease
infarction 27 37 27 37 I-chronic_disease

Age 0 3 38 41 B-age
at 4 6 42 44 O
screening 7 16 45 54 O
≥ 17 18 55 56 O
18 19 21 57 59 B-lower_bound
years 22 27 60 65 I-lower_bound
for 28 31 66 69 O
male 32 36 70 74 B-gender
and 37 40 75 78 O
permanently 41 52 79 90 O
sterilized 53 63 91 101 O

Body 0 4 102 106 B-bmi
Mass 5 9 107 111 I-bmi
Index 10 15 112 117 I-bmi
( 16 17 118 119 I-bmi
BMI 17 20 119 122 I-bmi
) 20 21 122 123 I-bmi
≥ 22 23 124 125 O
18.5 24 28 126 130 B-lower_bound
and 29 32 131 134 O
< 33 34 135 136 O
45 35 37 137 139 B-upper_bound
kg 38 40 140 142 I-upper_bound
/ 40 41 142 143 I-upper_bound
m2 41 43 143 145 I-upper_bound

Confirmed 0 9 146 155 O
non 10 13 156 159 B-chronic_disease
- 13 14 159 160 I-chronic_disease
diabetic 14 22 160 168 I-chronic_disease
renal 23 28 169 174 I-chronic_disease
disease 29 36 175 182 I-chronic_disease
in 37 39 183 185 O
the 40 43 186 189 O
opinion 44 51 190 197 O
of 52 54 198 200 O
investigator 55 67 201 213 O

Male 0 4 214 218 B-gender
patients 5 13 219 227 I-gender
with 14 18 228 232 O
partners 19 27 233 241 O
of 28 30 242 244 O
child 31 36 245 250 O
- 36 37 250 251 O
bearing 37 44 251 258 O
potential 45 54 259 268 O
must 55 59 269 273 O
be 60 62 274 276 O
willing 63 70 277 284 O
to 71 73 285 287 O
use 74 77 288 291 O
condoms 78 85 292 299 O
from 86 90 300 304 O
the 91 94 305 308 O
time 95 99 309 313 O
of 100 102 314 316 O
the 103 106 317 320 O
first 107 112 321 326 O
intake 113 119 327 333 O
of 120 122 334 336 O
study 123 128 337 342 O
drug 129 133 343 347 O
until 134 139 348 353 O
follow 140 146 354 360 O
- 146 147 360 361 O
up 147 149 361 363 O

Medical 0 7 364 371 O
history 8 15 372 379 O
of 16 18 380 382 O
cancer 19 25 383 389 B-cancer
or 26 28 390 392 O
treatment 29 38 393 402 B-treatment
for 39 42 403 406 O
cancer 43 49 407 413 O
in 50 52 414 416 O
the 53 56 417 420 O
last 57 61 421 425 B-upper_bound
two 62 65 426 429 I-upper_bound
years 66 71 430 435 I-upper_bound
prior 72 77 436 441 I-upper_bound
to 78 80 442 444 O
Visit 81 86 445 450 O
1 87 88 451 452 O
( 89 90 453 454 O
except 90 96 454 460 O
appropriately 97 110 461 474 O
treated 111 118 475 482 O
basal 119 124 483 488 B-cancer
cell 125 129 489 493 I-cancer
carcinoma 130 139 494 503 I-cancer
of 140 142 504 506 I-cancer
the 143 146 507 510 I-cancer
skin 147 151 511 515 I-cancer
, 151 152 515 516 O
in 153 155 517 519 B-cancer
situ 156 160 520 524 I-cancer
carcinoma 161 170 525 534 I-cancer
of 171 173 535 537 I-cancer
uterine 174 181 538 545 I-cancer
cervix 182 188 546 552 I-cancer
, 188 189 552 553 O
and 190 193 554 557 O
prostatic 194 203 558 567 B-cancer
cancer 204 210 568 574 I-cancer
of 211 213 575 577 I-cancer
low 214 217 578 581 I-cancer
grade 218 223 582 587 I-cancer
[ 224 225 588 589 I-cancer
T1 225 227 589 591 I-cancer
or 228 230 592 594 I-cancer
T2 231 233 595 597 I-cancer
] 233 234 597 598 I-cancer
is 235 237 599 601 O
exempted 238 246 602 610 O
) 246 247 610 611 O

Patients 0 8 612 620 O
with 9 13 621 625 O
type 14 18 626 630 B-lower_bound
1 19 20 631 632 I-lower_bound
or 21 23 633 635 O
type 24 28 636 640 B-upper_bound
2 29 30 641 642 I-upper_bound
diabetes 31 39 643 651 B-clinical_variable
mellitus 40 48 652 660 I-clinical_variable
, 48 49 660 661 O
diagnosed 50 59 662 671 O
before 60 66 672 678 O
informed 67 75 679 687 O
consent 76 83 688 695 O
and 84 87 696 699 O
treated 88 95 700 707 O
with 96 100 708 712 O
insulin 101 108 713 720 B-treatment
, 108 109 720 721 O
glucagon 110 118 722 730 B-treatment
- 118 119 730 731 I-treatment
like 119 123 731 735 I-treatment
peptide 124 131 736 743 I-treatment
( 132 133 744 745 I-treatment
GLP 133 136 745 748 I-treatment
) 136 137 748 749 I-treatment
1 138 139 750 751 I-treatment
agonists 140 148 752 760 I-treatment
and/or 149 155 761 767 O
oral 156 160 768 772 B-treatment
antidiabetic 161 173 773 785 I-treatment
medication 174 184 786 796 I-treatment

Treatment 0 9 797 806 O
should 10 16 807 813 O
have 17 21 814 818 O
been 22 26 819 823 O
unchanged 27 36 824 833 O
( 37 38 834 835 O
investigator 38 50 835 847 O
's 50 52 847 849 O
judgment 53 61 850 858 O
) 61 62 858 859 O
within 63 69 860 866 O
4 70 71 867 868 B-upper_bound
weeks 72 77 869 874 I-upper_bound
before 78 84 875 881 O
Visit 85 90 882 887 O
1 91 92 888 889 O
and 93 96 890 893 O
until 97 102 894 899 O
randomisation 103 116 900 913 O

Treatment 0 9 914 923 B-treatment
with 10 14 924 928 O
SGLT2 15 20 929 934 B-treatment
inhibitors 21 31 935 945 I-treatment
and/or 32 38 946 952 O
phosphodiesterase 39 56 953 970 B-treatment
inhibitors 57 67 971 981 I-treatment
, 67 68 981 982 O
nitrates 69 77 983 991 B-treatment
or 78 80 992 994 O
riociguat 81 90 995 1004 B-treatment
, 90 91 1004 1005 O
from 92 96 1006 1010 O
screening 97 106 1011 1020 O
( 107 108 1021 1022 O
Visit 108 113 1022 1027 O
1 114 115 1028 1029 O
) 115 116 1029 1030 O
or 117 119 1031 1033 O
within 120 126 1034 1040 O
5 127 128 1041 1042 O
half 129 133 1043 1047 O
- 133 134 1047 1048 O
lives 134 139 1048 1053 O
before 140 146 1054 1060 O
randomisation 147 160 1061 1074 O
whatever 161 169 1075 1083 O
is 170 172 1084 1086 O
earlier 173 180 1087 1094 O

Treatment 0 9 1095 1104 O
with 10 14 1105 1109 O
either 15 21 1110 1116 O
ACEi 22 26 1117 1121 B-treatment
or 27 29 1122 1124 O
ARB 30 33 1125 1128 B-treatment
, 33 34 1128 1129 O
stable 35 41 1130 1136 O
dose 42 46 1137 1141 O
since 47 52 1142 1147 O
≥ 53 54 1148 1149 O
4 55 56 1150 1151 B-lower_bound
weeks 57 62 1152 1157 I-lower_bound
before 63 69 1158 1164 O
Visit 70 75 1165 1170 O
1 76 77 1171 1172 O
with 78 82 1173 1177 O
no 83 85 1178 1180 O
planned 86 93 1181 1188 O
change 94 100 1189 1195 O
of 101 103 1196 1198 O
the 104 107 1199 1202 O
therapy 108 115 1203 1210 O

UACR 0 4 1211 1215 B-clinical_variable
≥ 5 6 1216 1217 O
200 7 10 1218 1221 B-lower_bound
and 11 14 1222 1225 O
< 15 16 1226 1227 O
3500 16 20 1227 1231 B-upper_bound
mg 21 23 1232 1234 I-upper_bound
/ 23 24 1234 1235 I-upper_bound
g 24 25 1235 1236 I-upper_bound
in 26 28 1237 1239 O
spot 29 33 1240 1244 O
urine 34 39 1245 1250 O
( 40 41 1251 1252 O
midstream 41 50 1252 1261 O
urine 51 56 1262 1267 O
sample 57 63 1268 1274 O
) 63 64 1274 1275 O
at 65 67 1276 1278 O
Visit 68 73 1279 1284 O
1 74 75 1285 1286 O
measured 76 84 1287 1295 O
by 85 87 1296 1298 O
the 88 91 1299 1302 O
central 92 99 1303 1310 O
laboratory 100 110 1311 1321 O

Women 0 5 1322 1327 B-gender
of 6 8 1328 1330 O
childbearing 9 21 1331 1343 O
potential 22 31 1344 1353 O

bilateral 0 9 1354 1363 O
salpingectomy 10 23 1364 1377 B-treatment

clinically 0 10 1378 1388 O
relevant 11 19 1389 1397 O
arrhythmias 20 31 1398 1409 B-chronic_disease

coronary 0 8 1410 1418 B-chronic_disease
heart 9 14 1419 1424 I-chronic_disease
disease 15 22 1425 1432 I-chronic_disease
not 23 26 1433 1436 O
compensated 27 38 1437 1448 O
by 39 41 1449 1451 O
medical 42 49 1452 1459 B-treatment
treatment 50 59 1460 1469 I-treatment
( 60 61 1470 1471 O
supine 61 67 1471 1477 B-clinical_variable
pulse 68 73 1478 1483 I-clinical_variable
rate 74 78 1484 1488 I-clinical_variable
> 79 80 1489 1490 O
70 80 82 1490 1492 B-lower_bound
beats 83 88 1493 1498 I-lower_bound
per 89 92 1499 1502 O
minute 93 99 1503 1509 O
, 99 100 1509 1510 O
existing 101 109 1511 1519 O
angina 110 116 1520 1526 B-chronic_disease
pectoris 117 125 1527 1535 I-chronic_disease
) 125 126 1535 1536 O

eGFR 0 4 1537 1541 B-clinical_variable
( 5 6 1542 1543 O
Chronic 6 13 1543 1550 B-clinical_variable
Kidney 14 20 1551 1557 I-clinical_variable
Disease 21 28 1558 1565 I-clinical_variable
Epidemiology 29 41 1566 1578 I-clinical_variable
Collaboration 42 55 1579 1592 I-clinical_variable
[ 56 57 1593 1594 I-clinical_variable
CKD 57 60 1594 1597 I-clinical_variable
- 60 61 1597 1598 I-clinical_variable
EPI 61 64 1598 1601 I-clinical_variable
] 64 65 1601 1602 I-clinical_variable
formula 66 73 1603 1610 I-clinical_variable
) 73 74 1610 1611 O
≥ 75 76 1612 1613 O
20 77 79 1614 1616 B-lower_bound
and 80 83 1617 1620 O
< 84 85 1621 1622 O
75 86 88 1623 1625 B-upper_bound
ml 89 91 1626 1628 I-upper_bound
/ 91 92 1628 1629 I-upper_bound
min/1.73 92 100 1629 1637 I-upper_bound
m2 101 103 1638 1640 I-upper_bound
at 104 106 1641 1643 O
Visit 107 112 1644 1649 O
1 113 114 1650 1651 O
measured 115 123 1652 1660 O
by 124 126 1661 1663 O
the 127 130 1664 1667 O
central 131 138 1668 1675 O
laboratory 139 149 1676 1686 O
and 150 153 1687 1690 O
no 154 156 1691 1693 O
planned 157 164 1694 1701 O
start 165 170 1702 1707 O
of 171 173 1708 1710 O
renal 174 179 1711 1716 B-treatment
replacement 180 191 1717 1728 I-treatment
therapy 192 199 1729 1736 I-treatment
during 200 206 1737 1743 O
the 207 210 1744 1747 O
trial 211 216 1748 1753 O

female 0 6 1754 1760 B-gender
patients 7 15 1761 1769 I-gender
and 16 19 1770 1773 O
≥ 20 21 1774 1775 O
45 22 24 1776 1778 B-lower_bound
years 25 30 1779 1784 I-lower_bound
for 31 34 1785 1788 O
postmenopausal 35 49 1789 1803 O
female 50 56 1804 1810 O
patients 57 65 1811 1819 O

known 0 5 1820 1825 O
history 6 13 1826 1833 O
of 14 16 1834 1836 O
tachycardia 17 28 1837 1848 B-chronic_disease
and/or 29 35 1849 1855 O
atrial 36 42 1856 1862 B-chronic_disease
fibrillation 43 55 1863 1875 I-chronic_disease

less 0 4 1876 1880 O
than 5 9 1881 1885 O
30 10 12 1886 1888 B-upper_bound
days 13 17 1889 1893 I-upper_bound
since 18 23 1894 1899 O
ending 24 30 1900 1906 O
another 31 38 1907 1914 O
investigational 39 54 1915 1930 O
device 55 61 1931 1937 O
or 62 64 1938 1940 O
drug 65 69 1941 1945 O
study(s 70 77 1946 1953 O
) 77 78 1953 1954 O

significant 0 11 1955 1966 O
blood 12 17 1967 1972 O
donation 18 26 1973 1981 O
( 27 28 1982 1983 O
investigator 28 40 1983 1995 O
's 40 42 1995 1997 O
judgement 43 52 1998 2007 O
) 52 53 2007 2008 O
within 54 60 2009 2015 O
four 61 65 2016 2020 B-upper_bound
weeks 66 71 2021 2026 I-upper_bound
prior 72 77 2027 2032 I-upper_bound
to 78 80 2033 2035 O
first 81 86 2036 2041 O
administration 87 101 2042 2056 O
of 102 104 2057 2059 O
study 105 110 2060 2065 O
medication 111 121 2066 2076 O
or 122 124 2077 2079 O
planned 125 132 2080 2087 O
during 133 139 2088 2094 O
the 140 143 2095 2098 O
trial 144 149 2099 2104 O

